Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2014 Publisher: Galen Limited, Seagoe Industrial Estate, Craigavon, BT63 5UA, UK
DaunoXome 2 mg/mL concentrate for solution for infusion.
Pharmaceutical Form |
---|
Concentrate for solution for infusion. Each vial contains a translucent red liposomal dispersion free from visible particles. |
Daunorubicin present as citrate salt; equivalent to daunorubicin base, 2 mg/ml, encapsulated in liposomes.
Each single dose vial of DaunoXome contains 50 mg daunorubicin.
For excipients, see Section 6.1.
Active Ingredient | Description | |
---|---|---|
Daunorubicin |
Daunorubicin is an anthracycline glycoside antibiotic and is a potent antileukaemic agent. It also has immunosuppressant effects. Daunorubicin may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction. |
List of Excipients |
---|
Liposome: Colfosceril stearate Buffer: Sucrose |
DaunoXome is presented in 50-ml sterile Type 1glass Ph. Eur. vial. Each vial contains 25 ml liquid for infusion. The closure consists of a butyl rubber stopper and aluminum ring seal fitted with a removable plastic cap. Each single-dose vial is packed in a white chipboard carton. Included in each carton are directions for use.
Pack size 1 × 25 mL.
Galen Limited, Seagoe Industrial Estate, Craigavon, BT63 5UA, UK
PA1329/009/001
Date of first authorisation: 01 May 1996
Date of last renewal: 24 May 2010
Drug | Countries | |
---|---|---|
DAUNOXOME | Estonia, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.